Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 3046
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Mapk3
Name: mitogen activated protein kinase 3
Acc ID: CHEBI:5118
Term: fluoxetine
Definition: A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
Chemical ID: MESH:D005473
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Mapk3increases expressionEXP 6480464CTDFluoxetine results in increased expression of MAPK3 proteinPMID:15138445
Mapk3multiple interactionsEXP 6480464CTDFluoxetine results in increased phosphorylation of and results in increased activity of MAPK3 protein; N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [Fluoxetine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Fluoxetine results in increased phosphorylation of and results in increased activity of MAPK3 protein]PMID:15456934 PMID:18573488
Mapk3decreases phosphorylationISOMAPK3 (Homo sapiens)6480464CTDFluoxetine results in decreased phosphorylation of MAPK3 proteinPMID:18836303
Mapk3increases expressionISOMapk3 (Mus musculus)6480464CTDFluoxetine results in increased expression of MAPK3 proteinPMID:19477151
Mapk3increases phosphorylationISOMapk3 (Mus musculus)6480464CTDFluoxetine results in increased phosphorylation of MAPK3 proteinPMID:16413968 PMID:18758753 PMID:24125781
Mapk3multiple interactionsISOMapk3 (Mus musculus)6480464CTD1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; [[Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK3 protein] which results in increased expression of PLA2G4A protein; [[Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK3 protein; [Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein; ADARB1 protein inhibits the reaction [Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Fluoxetine results in increased expression of MAPK3 protein]; bisindolylmaleimide I inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; Calcium promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK3 protein]; HTR2B protein inhibits the reaction [Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK3 protein]]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]PMID:18758753 PMID:19477151 PMID:19662385 PMID:21320410
Go Back to source page   Continue to Ontology report